Valiant Laboratories
- Market cap
- ₹ 702 Cr.
- P/E
- 42.7x
- P/B
- 2.29x
- 52-week range
- 49.51 – 141.38
- ROE
- −1%
- ROCE
- 1%
- Dividend yield
- 0%
- Debt / equity
- 0.15
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Valiant Laboratories Limited is an India-based pharmaceutical ingredient manufacturing company. The Company is focused on manufacturing a Paracetamol active pharmaceutical ingredient (API)/bulk drug. It has several applications in the treatment of conditions such as headache, muscle ache, arthritis, backache, toothache, cold and fever. It is also used in the management of severe pain such as post-surgical and cancer pain. It operates a single-location manufacturing facility on the Tarapur industrial estate.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Valiant Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)42.7 against a typical 34.3: pricier than most peers (1st = cheapest).139th of 220
- Sales growth+144.7% against a typical +15.6% from a year earlier.12th of 197
- Profit growth+950% against a typical +18.9% from a year earlier.6th of 160
- Share price, 3 months+103.8% against a typical −0.5%.4th of 200
- Size₹ 702 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).94th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB by India Ratings- CRISIL lowered its rating on 30 Jun 2026.
- The company stopped sharing information with CRISIL.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND BBB; IND A2 | Stable | 3 Sep 2026 |
| CRISIL | Crisil BB(Issuer Not Cooperating) | Stable | 30 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 3 Sep 2026 | Reaffirmed | IND BBB | — | India Ratings | ₹ 56 Cr. | |
| 30 Jun 2026 | ▼ Downgrade1 notch | Crisil BB+ (Issuer Not Cooperating) → Crisil BB(Issuer Not Cooperating) | — | CRISIL | ₹ 50 Cr. | |
| 18 Nov 2025 | Rating action | Crisil BB+ (Issuer Not Cooperating) | — | CRISIL | ₹ 50 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 14 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 9 Jul 2025 | Fund Raising | To consider Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 41 | 31 | 19 | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses | 61 | 47 | 35 | 21 | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating Profit | −1 | −6 | −5 | −2 | −7 | 1 | 4 | 2 | 0 | −1 | 5 | 29 |
| OPM % | −2.3% | −16% | −15% | −13% | −31% | 1.8% | 7% | 5% | 0.2% | −1.7% | 5% | 25% |
| Other Income | 3 | 2 | 2 | 3 | 3 | 2 | −2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | 1 | −5 | −3 | 0 | −4 | 2 | 1 | 2 | 0 | −3 | 1 | 26 |
| Tax % | 25% | −31% | −52% | 219% | 21% | −44% | 26% | 26% | 25% | 136% | −68% | 19% |
| Net Profit | 1 | −4 | −1 | −1 | −5 | 2 | 1 | 2 | 0 | −7 | 2 | 21 |
| EPS in Rs | 0.19 | −0.64 | −0.23 | −0.09 | −0.87 | 0.43 | 0.13 | 0.34 | 0.04 | −1.3 | 0.32 | 3.88 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −11%
- TTM
- 90%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 12,208%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Valiant Laboratories | ₹ 125.82 | ₹ 702 Cr. | 42.7x | 2.3x | −1% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Paresh Shashikant Shah
- Chief Financial Officer, Whole-Time Director
- Akshay Dnyaneshwar Gangurde
- Compliance Officer, Company Secretary
- Santosh Shantilal Vora
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.